10x Genomics [TXG] vs HealthEquity [HQY] Detailed Stock Comparison

10x Genomics Inc.

NASDAQ
Loading...

HealthEquity Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: 10x Genomics Inc. wins in 4 metrics, HealthEquity Inc. wins in 15 metrics, with 0 ties. HealthEquity Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric 10x Genomics Inc. HealthEquity Inc. Better
P/E Ratio (TTM) -63.09 31.61 HealthEquity Inc.
Price-to-Book Ratio 3.54 3.14 HealthEquity Inc.
Debt-to-Equity Ratio 10.59 47.53 10x Genomics Inc.
PEG Ratio 0.93 0.34 HealthEquity Inc.
EV/EBITDA -37.16 15.04 HealthEquity Inc.
Profit Margin (TTM) -6.77% 16.39% HealthEquity Inc.
Operating Margin (TTM) -9.42% 21.64% HealthEquity Inc.
EBITDA Margin (TTM) N/A 21.64% N/A
Return on Equity -5.78% 10.19% HealthEquity Inc.
Return on Assets (TTM) -6.40% 5.99% HealthEquity Inc.
Free Cash Flow (TTM) $130.12M $408.32M HealthEquity Inc.
1-Year Return 177.04% -15.67% 10x Genomics Inc.
Price-to-Sales Ratio (TTM) 4.39 5.00 10x Genomics Inc.
Enterprise Value $2.38B $7.25B HealthEquity Inc.
EV/Revenue Ratio 3.71 5.52 10x Genomics Inc.
Gross Profit Margin (TTM) 68.09% 68.19% HealthEquity Inc.
Revenue per Share (TTM) $5 $15 HealthEquity Inc.
Earnings per Share (Diluted) $-0.35 $2.46 HealthEquity Inc.
Beta (Stock Volatility) 2.17 0.26 HealthEquity Inc.
Short % of Float 20.38% 4.74% HealthEquity Inc.

10x Genomics Inc. vs HealthEquity Inc. Stock Performance Analysis

Loading Price Chart...

TXG
HQY

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
10x Genomics Inc.11.72%10.42%51.98%93.05%104.44%93.86%
HealthEquity Inc.-1.55%-0.99%5.84%10.55%-9.17%-4.50%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
10x Genomics Inc.177.04%-50.37%-85.17%-44.82%-44.82%-44.82%
HealthEquity Inc.-15.67%41.37%14.18%203.78%421.18%421.18%

Performance & Financial Health Analysis: 10x Genomics Inc. vs HealthEquity Inc.

MetricTXGHQY
Market Information
Market Cap i$2.82B$6.57B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i2,733,1601,020,070
90 Day Avg. Volume i2,471,3331,022,103
Last Close$32.22$86.97
52 Week Range$10.17 - $35.65$72.76 - $106.60
% from 52W High-9.61%-18.41%
All-Time High$208.99 (Jun 28, 2021)$116.65 (Jun 05, 2025)
% from All-Time High-84.58%-25.44%
Growth Metrics
Quarterly Revenue Growth0.01%0.07%
Quarterly Earnings Growth0.01%0.89%
Financial Health
Profit Margin (TTM) i-0.07%0.16%
Operating Margin (TTM) i-0.09%0.22%
Return on Equity (TTM) i-0.06%0.10%
Debt to Equity (MRQ) i10.5947.53
Cash & Liquidity
Book Value per Share (MRQ)$6.24$24.79
Cash per Share (MRQ)$4.10$3.78
Operating Cash Flow (TTM) i$136.05M$457.09M
Levered Free Cash Flow (TTM) i$148.39M$338.05M
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: 10x Genomics Inc. vs HealthEquity Inc.

MetricTXG (Apr 26, 2026)HQY (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i-63.0931.61
Forward P/E i110.4014.56
PEG Ratio i0.930.34
Price to Sales (TTM) i4.395.00
Price to Book (MRQ) i3.543.14
Market Capitalization
Market Capitalization i$2.82B$6.57B
Enterprise Value i$2.38B$7.25B
Enterprise Value Metrics
Enterprise to Revenue i3.715.52
Enterprise to EBITDA i-37.1615.04
Risk & Other Metrics
Beta i2.170.26
Book Value per Share (MRQ) i$6.24$24.79

Financial Statements Comparison: 10x Genomics Inc. vs HealthEquity Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricTXG (2025)HQY (2026)
Revenue/Sales i642.82M1.31B
Cost of Goods Sold i198.94M400.31M
COGS % of Revenue i30.9%30.5%
Gross Profit i443.88M913.12M
Gross Margin i69.1%69.5%
Research & Development i238.63M262.51M
Operating Income (EBIT) i-110.89M327.48M
Operating Margin i-17.2%24.9%
EBITDA i-45.99M494.24M
EBITDA Margin i-7.2%37.6%
Pre-Tax Income i-39.91M277.43M
Pre-Tax Income % of Revenue i-6.2%21.1%
Income Tax i3.64M62.23M
Income Tax % of Revenue i0.6%4.7%
Net Income (Profit) i-43.54M215.20M
Profit Margin i-6.8%16.4%

Balance Sheet & Liquidity Metrics

MetricTXG (2025)HQY (2026)
Cash & Equivalents i473.97M318.93M
Total Current Assets i684.45M512.28M
Total Current Assets % of Revenue i106.5%39.0%
Total Current Liabilities i153.45M156.85M
Total Current Liabilities % of Revenue i23.9%11.9%
Long-Term Debt i73.38M991.57M
Long-Term Debt % of Revenue i11.4%75.5%
Total Shareholders Equity i796.33M2.11B
Retained Earnings i-1.51B195.91M
Retained Earnings % of Revenue i-235.0%14.9%
Property, Plant & Equipment i60.45M36.31M

Cash Flow Statement Comparison

MetricTXG (2025)HQY (2026)
Operating Cash Flow i141.48M457.11M
Operating Cash Flow % of Revenue i22.0%34.8%
Capital Expenditures i-5.94M-1.97M
Free Cash Flow i130.12M408.32M
FCF Margin i20.2%31.1%
Debt Repayment iN/A-100.00M
Common Stock Repurchase iN/A-299.25M

Short Interest & Institutional Ownership Analysis

MetricTXGHQY
Shares Short i16.47M3.45M
Short Ratio i6.843.52
Short % of Float i20.38%4.74%
Shares Outstanding i127.69M85.01M
Float Shares i115.49M82.74M
% Held by Insiders i1.81%2.32%
% Held by Institutions i108.01%109.95%
% Held by Public i-9.82%-12.27%

Dividend Analysis & Yield Comparison: 10x Genomics Inc. vs HealthEquity Inc.

MetricTXGHQY
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A